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Introduction 
Mendelian randomization studies are increasingly being used to evaluate the potential efficacy and 
safety of medical therapies as a strategy to provide genetic target validation.1-7 The first step in this 
process is to create an instrumental variable consisting of variants in or around the gene that 
encodes the target of a therapy that are associated with changes in a biomarker that reflects the 
pharmacologic action of the therapy.  
 
The genes that encode the targets of some therapies include large-effect loss-of-function (or partial 
loss-of-function) variants that can be used “instrument” the effect of a therapy.8  If such a variant is 
associated with a quantitatively large change in the biomarker that reflects the pharmacologic effect 
of a therapy directed against the target encoded by the gene, and is associated with a corresponding 
improvement in a clinically relevant outcome measure, then this variant can provide genetic target 
validation for the therapy under study.   Indeed, developing therapies that have genetic target 
validation doubles the success rate of therapies that reach clinical trials, from 5-10% to 10-20%.9  
While this may fundamentally improve the cost structure of drug development, it still means that 
80-90% of therapies directed against genetically validated targets will fail in clinical development! 
 
The reason for this startling expected failure rate of therapies directed against “genetically validated 
targets” is that genetic target validation is not enough to ensure that a therapy directed against the 
target will produce a clinically meaningful reduction in the risk of the outcome of interest. Instead, 
instead genetic target validation is analogous to early stage drug development. This can be 
understood intuitively by recognizing that large-effect variants tend to be rare. As a result, the 
estimate of the quantitative magnitude of the observed effect must be viewed with caution because 
it is generally imprecise with vary wide confidence intervals.  
 
To fill the “translational gap” between discovering genetically validated targets and informing the 
clinical development of those therapies, it is necessary to conduct a number of additional steps 
beyond genetic target validation to use naturally randomized genetic evidence to estimate the 
potential clinical benefit of a therapy directed against a genetically validated target. This can be 
accomplished by combining two or more common variants in or around the gene encoding a therapy 
into a genetic score constructed as an instrumental variable.  If the common variants included in the 
instrumental variable genetic score are associated with at least a moderate effect on changes in the 
biomarker reflecting the pharmacologic action of the therapy it is being used to instrument, then 
such a genetic score can be used to establish what the causal biomarker is (from a list of biologically 
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related biomarkers altered by the therapy).10,11 If this type of type of genetic instrument is robust 
enough, it can also be used to assess the magnitude and shape of the causal dose response curve.6,10 
This information is critical for determining how much the causal biomarker must be altered to 
produce clinically important effect in a short-term trial to estimate the potential clinical relevance of 
a therapy directed against the therapeutic target thus guiding clinical development and informing 
the design of randomized trials evaluating the therapy. 
 
Unfortunately, the genes that encode the target of the vast majority of available therapies do have 
either rare variants that are associated with a large effect on the biomarker of interest, or any 
common variants that have at least a moderate effect on that biomarker.  In this case, multiple 
common variants in or around the gene encoding the target of the therapy that have a weak effect 
on the biomarker reflecting the pharmacologic action of the therapy must be combined into an 
instrumental variable genetic score.  The optimal method to construct an instrumental variable 
genetic score consisting of several weak effect common variants designed to “instrument” a therapy 
is unclear.  Here, we describe one strategy used to overcome this problem in the context of a 
recently published study, with updated analyses and results.7 
 
A strategy to overcome challenges in constructing genetic instruments for pharmacologic therapies 
 
ATP citrate lyase (ACL) is an enzyme located upstream to HMG-CoA reductase in the cholesterol 
biosynthesis pathway.12 Inhibiting ACL with bempedoic acid has been shown to reduce plasma LDL-C 
in several early phase randomized clinical trials.13-15  Thus, ACL is a biologically validated therapeutic 
target. 
 
Furthermore, numerous randomized trials have demonstrated that lowering plasma LDL-C by 
inhibiting the cholesterol biosynthesis pathway by inhibiting HMG-CoA reductase with a statin, 
NPC1L1 with ezetimibe, or PCSK9 with an antibody reduces plasma LDL-C and reduces the risk of 
cardiovascular events.16-20  Thus, the cholesterol biosynthesis pathway is a clinically validated 
therapeutic target. 
 
The objective of our study therefore was not to provide “genetic target validation” for ACLY, the 
gene that encodes ACL, but instead to construct a genetic instrument that mimics the clinical effects 
of inhibiting ACL to provide a biological context for interpreting the results of prior ACL inhibitor 
randomized trials, inform the design of future ACL inhibitor randomized trials, and estimate the 
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clinical effect of lowering plasma LDL-C by inhibiting ACL.7  We have used this approach to construct 
genetic instruments that mimic the effect of HMGCR, NPC1L1, PCSK9 and CETP inhibitors in the past 
to successfully anticipate the results of several landmark randomized clinical trials evaluating these 
agents (IMPROVE-IT, FOURIER, and REVEAL).3,4,5,16,17,21   
 
The challenge in conducting the current study was that, unlike for HMGCR, NPC1L1 and PCSK9 genes, 
there are no rare or common variants in the ACLY gene region that are strongly associated with 
changes in plasma LDL-C.  To solve this problem, we developed an expanded approach to develop 
genetic instruments that mimic the effect of therapies directed against existing targets. This process 
involved several steps. 
 
First, we chose to expand the window around the ACLY gene by 500 Kb in either direction to include 
a greater number of candidate genetic variants with weak effects on LDL-C that could potentially be 
included in our genetic ACLY score designed to instrument ACL inhibition.  The justification for this 
decision was two-fold.  First, we noted that genetic variants reported to be associated with ACLY 
expression in the Genotype-Tissue Expression (GTEx) project span a region of 1.7 Mb around the 
ACLY gene (970 Kb upstream and 670 Kb downstream).22  Thus, circumscribing the window around 
ACLY to a smaller subset of this region maximized the probability that we could potentially include 
variants in our ACL instrument that were associated with both LDL-C and ACLY gene expression, even 
though they were not located physically close to the gene.  Second, we noted that of the 33 genes 
included in this relatively “gene-dense” region spanning 500 Kb on either side of ACLY gene, ACLY is 
the only gene in this region that encoded a protein (ACL) that is both a) known to be involved in lipid 
metabolism (both cholesterol biosynthesis and the intrinsic fatty acid pathway), and b) results in 
lower plasma LDL-C when inhibited (with the ACL inhibitor bempedoic acid). 
 
Second, because all variants in this region have at most weak effects on LDL-C, we developed a 
machine learning algorithm to identify and select variants for inclusion in the ACLY score.  To 
maximize computational efficiency, the machine learning algorithms designed to identify variants for 
inclusion in the ACLY score used the public summary data provided by the MAGNETIC consortium.23  
The MAGNETIC summary data were used rather than the larger public Global Lipids Genetics 
Consortium data because MAGNETIC had imputed data available for a much larger number of 
genetic variants.   The objective of the machine learning algorithm was to identify the group of 
genetic variants in this gene region that - in combination – had the strongest association with LDL-C, 
which is the main pharmacologic effect of ACL inhibition. A list of the genetic variants that in 
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combination had the strongest association with LDL-C and that were included in the ACLY score 
ultimately used in our study, and their individual marginal effect sizes for LDL-C as reported in the 
public MAGNETIC data was provided as Table S3 in the appendix to our manuscript (Table S3: ACLY 
variants included in ACL score and associations with plasma LDL-C);7 and is reproduced here: 
 
 
Table 1:  Individual ACLY score variants associations with LDL-C in MAGNETIC GWAS 
 
variant Exposure 
allele 
Exposure allele 
frequency 
LDL Effect Size 
(mg/dl) 
LDL SE 
rs34349578 G 0.7793 -0.7495 0.4024 
rs55674565 T 0.3794 -0.8229 0.3246 
rs2883233 C 0.1388 -1.697 0.5536 
rs117335915 T 0.9782 -3.4469 1.2869 
rs113201466 G 0.9498 -1.8535 0.7931 
rs62075782 G 0.7774 -0.9837 0.4255 
rs145940140 T 0.9907 -5.0301 2.2423 
rs143382920 A 0.9931 -4.1152 2.1669 
rs117981684 G 0.9789 -3.1242 1.1684 
     
Inverse-variance Meta-analysis  P=6.4E-10 -1.173 0.1898 
(one unit change in score)     
 
NB: MAGNETIC data used for screening in the machine learning algorithm to identify best genetic score 
 
 
Importantly, because all variants in the ACLY gene region have at most a weak statistical association 
with LDL-C, using a machine learning algorithm to select variants for inclusion into a score based on 
their weak statistical associations with LDL-C can potentially “overfit” the data by selecting variants 
that happen to be weakly associated with plasma LDL-C levels by chance alone.  Combining several 
variants that are weakly associated with LDL-C by chance into a combined score could potentially 
create a score that is strongly associated with LDL-C due to the compounding effect of multiple 
chance associations.      
 
To address this over-fitting issue, the machine-learning algorithm selected variants for inclusion in 
the ACLY genetic score using the following protocol.  First, a random sample of 50% of the variants 
within a 500 KB window of the ACLY gene was sampled. The variants were then ranked by the 
strength of their association with LDL-C (z score).  The variant most strongly associated with LDL-C 
was selected for inclusion in the candidate ACLY score.  All variants correlated with the most strongly 
associated variant at an r2 > 0.3 were then removed from the remaining set of candidate variants.  
Next, a random sample of 50% of the remaining candidate variants was sampled. The variant with 
strongest association with LDL-C was then added to the score, and all variants with an r2 > 0.3 with 
this variant were then removed from the set of candidate variants. This process repeated iteratively 
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until all variants were either selected, removed due to linkage disequilibrium with a selected variant, 
or were not associated (p > 0.05) with plasma LDL-C in the MAGNETIC NMR GWS.  This overall 
process was then repeated 1000 times to create a portfolio of candidate ACLY instruments. 
 
To further minimize the potential for “over-fitting”, we did not rely on the machine learning 
algorithm alone to construct the ACLY genetic score.  Instead, the construction of the ACLY score 
followed an iterative three stage process.  The first step was the machine learning algorithm 
designed to identify the groups of variants within the defined gene region that – in combination - 
had the strongest association with LDL-C as described immediately above.   
 
Next, each candidate ACLY score generated using this machine learning algorithm was then ranked 
by the strength of the association of the overall score with plasma LDL-C. For the most strongly 
associated ACLY score, the variants included in this “candidate score” were then evaluated in an 
independent sample using individual participant data (originally dbGAP studies and later 
supplemented by the larger INTERVAL study data to improve power)24,25 for evidence of 
conditionally independent associations with LDL-C at p< 0.05 as described in the appendix of our 
manuscript.7  The conditional associations with LDL-C were estimated in a linear regression model 
where the dependent variable was plasma LDL-C and the independent variables were age, sex, study 
sample, and 5 principal components of ancestry among participants who were free of cardiovascular 
disease at baseline and for whom one or more measurements of plasma lipids and lipoproteins was 
available.  The candidate ACLY score was rejected unless all variants included in the score were 
associated with LDL-C at nominal level of significance (p<0.05) conditional on the effect of all other 
variants included in the score.  This process repeated iteratively until the ACLY score that had the 
strongest overall association with LDL-C, and for which each variant included in the score was 
conditionally associated with LDL-C, was identified.   
 
As stated in the appendix to our manuscript, the conditional associations for each variant with LDL-C 
were used as weights in constructing the “weighted” genetic ACLY scores.7  The conditional 
associations with LDL-C for each variant included in the selected ACLY score ultimately used in our 
study is shown in Table 2 below: 
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Table 2:  Individual ACLY score variants conditional associations with LDL-C using individual participant data (INTERVAL and 
dbGAP) 
 
variant Exposure allele Exposure allele 
frequency 
LDL Effect Size 
(mg/dl) 
LDL SE 
rs34349578 G 0.779 -0.94 0.45 
rs55674565 T 0.379 -1.25 0.44 
rs2883233 C 0.130 -0.68 0.35 
rs117335915 T 0.978 -1.83 0.66 
rs113201466 G 0.950 -0.99 0.44 
rs62075782 A 0.223 -0.98 0.31 
rs145940140 T 0.991 -1.97 0.52 
rs143382920 A 0.993 -1.19 0.43 
rs117981684 G 0.979 -0.84 0.36 
     
Inverse-variance Meta-analysis  p = 9.2E-15 -1.064 0.1375 
(one unit change in score)     
Analyses incorporating partial 
correlation between variants 
 p = 3.4E-16 -1.2121 0.1486 
     
 
NB: In conditional analyses, the rs62075782 allele associated with lower LDL-C was opposite to that in MAGNETIC. Because, 
the conditional analyses were the primary weighting exposure, the A allele for rs62075782 was defined as the exposure 
allele (associated with lower LDL-C in conditional analyses) for all subsequent analyses.  
 
 
(We note well here that data in Table S3 of our manuscript, and reproduced as Table 1 above, are 
the LDL-C effect sizes for each variant as reported in the public MAGNETIC database which can be 
confirmed by a simple look-up of the public data. Therefore, the LDL-C effect sizes reported in Table 
S3 of the appendix to our manuscript were not the conditional LDL-C effect sizes for each variant as 
estimated using individual participant data from INTERVAL and dbGAP and presented in Table 2 
above.)  
 
Finally, in the third step the provisionally selected “candidate score” had to divide the population 
into two approximately equal halves (within the range of 40:60, or 60:40) when dichotomized above 
or below the median value for the unweighted and weighted genetic scores. This third criterion for 
selecting the best ACLY genetic score was necessary to facilitate the planned 2x2 factorial analysis of 
the separate and combined effects of genetic instruments that mimic ACL, HMGCR and NPC1L1 
inhibitors, respectively.  This was a very important consideration because in clinical medicine ACL 
inhibitors will be used almost exclusively in combination with either a statin or ezetimibe.   We note 
that within this construct, the combined effect of the variants included in the ACLY genetic score is 
the “instrument” that mimics ACL inhibition, not necessarily the effect of any individual variant 
included in the score.   
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The ACLY instrumental variable that fulfilled each of these three criteria was the one taken forward 
and used in all subsequent analyses.  
 
Associations of ACLY score with plasma LDL-C and apoB in UK Biobank 
 
Release of biomarker data from the UK Biobank, including data on LDL-C and apoB, released after 
our study was published provides an opportunity to determine whether our ACLY genetic score 
serves as an instrument that mimics the effect of ACL inhibition.26   
 
First, we note here that the rs62075782 allele associated with lower LDL-C was the A allele (EAF 
0.22) in conditional analyses but was the G allele in the summary MAGNETIC data.  Because the 
conditional effect size with LDL-C was defined as the weight for that variant, all analyses used the A 
allele (EAF 0.22) as the exposure allele for rs62075782.  Subsequent analysis using individual 
participant data from UK Biobank biomarker data released after publication of our manuscript 
CONFIRMED that the A allele (EAF 0.26 in UK Biobank) is the allele associated with lower LDL-C.   
 
Second, we note that variant rs34349578 did not pass Quality Control in UK Biobank, and therefore 
we used variant rs36005199 (r2=0.91) instead for all analyses involving UK Biobank participants.   
 
In the UK Biobank, our ACLY score is robustly associated with LDL-C. This is the third independent 
sample in which this score significantly associates with LDL-C.  Here it is important to note that the 
genetic instrument that we created to mimic ACL inhibition by design was the score itself (i.e. the 
combined effect of the variants included in the score).  The association between the ACLY genetic 
score and LDL-C, and marginal and conditional associations of each variant included in the score, is 
presented in Table 3: 
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Table 3:  Association of ACLY score and individual variants marginal and conditional associations with LDL-C in UK Biobank  
 
variant Exposure 
allele 
Exposure 
allele 
frequency 
Univariate 
LDL-C ES 
(mg/dl) 
Univariate 
LDL-C SE 
Univariate 
LDL-C  
P value 
Conditional 
LDL-C ES 
(mg/dl) 
Conditional 
LDL-C SE 
Conditional 
LDL-C 
P value 
rs36005199 G 0.779 -0.4949 0.0830 2.5E-09 -0.2153 0.1056 4.1E-02 
rs55674565 T 0.379 -0.2591 0.0764 7.0E-04 -0.2614 0.1031 1.1E-02 
rs2883233 C 0.130 -0.1603 0.0918 8.0E-02 -0.0777 0.1021 4.5E-01 
rs117335915 T 0.978 -0.3567 0.2000 7.5E-02 -0.3413 0.2038 9.5E-02 
rs113201466 G 0.950 -0.4531 0.1747 9.6E-03 -0.3723 0.1752 3.4E-02 
rs62075782 A 0.223 -0.4454 0.0879 4.0E-07 -0.5163 0.1032 5.7E-07 
rs145940140 T 0.991 1.0014 0.4555 2.8E-02 1.1499 0.4711 1.5E-02 
rs143382920 A 0.993 0.1374 0.2909 6.4E-01 -0.0095 0.3023 9.8E-01 
rs117981684 G 0.979 -0.1507 0.2763 5.8E-01 -0.2771 0.2786 3.2E-01 
         
Inverse-variance Meta-
analysis 
 -0.3251 0.0391 9.6E-17 -0.2592 0.0468 3.0E-08 
         
 
NB: rs34349578 did not pass QC in UK Biobank, so rs36005199 was used as the nearest proxy (r2=0.91). Data from 351,267 
participants of self-identified White ancestry not on current lipid lowering therapy, adjusted for age gender and the first 
five principal components 
 
 
As can be seen in Table 3, the ACLY score is robustly associated with LDL-C in the UK Biobank, using 
both marginal effect size estimates (p=9.6E-17) and conditional effect estimates (p=3.0E-08). 
 
Furthermore, when evaluated as a calculated score for each person in UK Biobank, the ACLY score 
remains robustly associated with plasma LDL-C both in analyses using the score as a continuous 
variable (p=3.7E-12) and as a dichotomous variable that acts as an unweighted instrument of 
randomization that divides participants into two groups with ACLY scores above or below the 
median value for the score (p=1.2E-09) 
 
Table 4:  Association of ACLY genetic scores with LDL-C in UK Biobank  
 
ACLY genetic score LDL-C effect size 
(mg/dl) 
LDL-C SE P value 
    
Unweighted genetic score as continuous variable -0.2277 0.0328 3.7E-12 
    
Unweighted genetic score as dichotomous variable 
(instrument of randomization) 
-0.6485 0.1067 1.2E-09 
    
 
NB: rs34349578 did not pass QC in UK Biobank, so rs36005199 was used as the nearest proxy (r2=0.91). Data from 351,267 
participants of self-identified White ancestry not on current lipid lowering therapy, adjusted for age gender and the first 
five principal components 
 
Furthermore, when combining data from the MAGNETIC, INTERVAL, dbGAP, and UK Biobank 
samples – all of which independently replicate the association of the instrument (i.e. the genetic 
score itself rather than the individual variants) the ACLY score was strongly associated with LDL-C 
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with an overall mean effect size per unit change in the score of -0.410 mg/dL (SE 0.0369), and a 
robust p value of 4.1E-29. 
 
In addition, the ACLY score was also robustly associated with apoB in the UK Biobank.  In all analyses 
the genetic instrument was robustly associated with lower plasma apoB, with p values ranging from 
5.5E-09 to 4.7E-18, as shown in Tables 5 and 6 below: 
 
Table 5:  Individual ACLY score variants marginal and conditional associations with apoB in UK Biobank  
 
variant Exposure 
allele 
Exposure allele 
frequency 
Univariate apoB 
ES (mg/dl) 
Univariate 
apoB SE 
Univariate apoB 
P value 
Conditional 
apoB ES 
(mg/dl) 
Conditional 
apoB SE 
Conditional apoB 
P value 
rs36005199 G 0.779 -0.3591 0.0610 4.1E-09 -0.1453 0.0776 6.1E-02 
rs55674565 T 0.379 -0.2083 0.0562 2.1E-04 -0.2122 0.0758 5.1E-03 
rs2883233 C 0.130 -0.1222 0.0675 7.0E-02 -0.0577 0.0751 4.4E-01 
rs117335915 T 0.978 -0.1845 0.1471 2.1E-01 -0.1549 0.1499 3.0E-01 
rs113201466 G 0.950 -0.3789 0.1285 3.2E-03 -0.3209 0.1289 1.3E-02 
rs62075782 A 0.223 -0.3261 0.0647 4.7E-07 -0.3898 0.0759 2.7E-07 
rs145940140 T 0.991 0.4477 0.3353 1.8E-01 0.6209 0.3468 7.3E-02 
rs143382920 A 0.993 -0.0702 0.2141 7.4E-01 -0.1728 0.2224 4.4E-01 
rs117981684 G 0.979 -0.1762 0.2031 3.8E-01 -0.2658 0.2048 1.9E-01 
         
Inverse-variance Meta-analysis -0.2493 0.0288 4.7E-18 -0.2012 0.0343 5.5E-09 
         
 
NB: rs34349578 did not pass QC in UK Biobank, so rs36005199 was used as the nearest proxy (r2=0.91). Data from 351,267 
participants of self-identified White ancestry not on current lipid lowering therapy, adjusted for age gender and the first 
five principal components 
 
 
 
Table 6:  Association of ACLY genetic scores with apoB in UK Biobank  
 
ACLY genetic score apoB effect size (mg/dl) apoB SE P value 
    
Unweighted genetic score as continuous variable -0.1745 0.0241 4.5E-13 
    
Unweighted genetic score as dichotomous variable 
(instrument of randomization) 
-0.4775 0.0785 1.2E-09 
    
 
NB: rs34349578 did not pass QC in UK Biobank, so rs36005199 was used as the nearest proxy (r2=0.91). Data from 351,267 
participants of self-identified White ancestry not on current lipid lowering therapy, adjusted for age gender and the first 
five principal components 
 
 
In addition, the ACLY instrument was associated with a ratio of lower aopB to lower LDL-C 
(apoB:LDL-C) of approximately 0.75, which is consistent with lowering LDL-C by removing LDL 
particles through up-regulation of the LDL receptor.  Therefore, by demonstrating that the ACLY 
score is robustly associated with both LDL-C and concordantly lower apoB, the UK Biobank data 
demonstrate that the ACLY score is instrumenting a gene that lowers LDL-C by lowering apoB 
particles through the LDL receptor.  The only gene in this region known to be associated with 
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lowering LDL-C through the LDL receptor is ACLY.  Indeed, these data provide further validation for 
the mechanism of action by which ACL inhibition reduces LDL-C – i.e. by reducing cholesterol 
biosynthesis leading to an up-regulation of the LDL receptor with subsequent clearing of circulating 
LDL particles resulting in a reduction in plasma LDL-C levels.    
 
Associations of ACLY score with cardiovascular events in the UK Biobank 
 
Release of the biomarker data from UK Biobank was also accompanied with release of updated data 
on clinical events, including major cardiovascular events and diabetes. 
 
In our manuscript, the associations for cardiovascular outcomes were reported for the 
approximately 100,000 cases of major coronary and cardiovascular outcomes in the combined data 
from CARDIoGRAMplusC4D and UK Biobank overall, and the combined data from UK Biobank and 
dbGAP for the factorial analyses.7  
 
As shown in Tables 7 and 8, both the weighted and unweighted ACLY score is robustly associated 
with CV events in the public summary data from 60,000 cases of CAD in the CARDIoGRAMplusC4D 
consortium studies and the individual participant data from the UK Biobank (using data prior to the 
recent update):    
 
Table 7:  Individual ACLY score variants unweighted associations with CAD in CARDIoGRAMplusC4D and UK Biobank 
 
variant Exposure 
allele 
CARDIoGRAM 
ES 
CARDIoGRAM 
SE 
UK Biobank 
ES 
UK Biobank 
SE 
rs36005199 G -0.0570 0.0124 -0.0204 0.0108 
rs55674565 T -0.0414 0.0097 -0.0184 0.0101 
rs2883233 C -0.0434 0.0168 -0.0093 0.0109 
rs117335915 T 0.0305 0.0348 -0.0221 0.0147 
rs113201466 G -0.0382 0.0226 -0.0153 0.0133 
rs62075782 A 0.00996 0.0151 -0.0146 0.0117 
rs145940140 T -0.0730 0.0687 -0.0241 0.0268 
rs143382920 A -0.0778 0.0650 -0.0169 0.0298 
rs117981684 G -0.0566 0.0336 0.0321 0.0387 
      
Inverse-variance Meta-analysis  -0.0356 0.0058 -0.0161 0.0046 
      
  ES SE OR (95%CI) 
Combined Cardiogram & UKBB  -0.0233 0.0035 0.977 (0.970-0.984) p=5.0E-11 
      
Adjusted per 10 mg/dl lower LDL-C  -0.1923 0.0293 0.825 (0.779-0.874)            
p=5.1E-11 
      
 
NB: rs34349578 did not pass QC in UK Biobank, so rs36005199 was used as the nearest proxy (r2=0.91) 
NB: adjusted for 10 mg/dl in unweighted analyses using the summary effect per unit change in ACLY score of 1.21 mg/dl  
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Table 8:  Individual ACLY score variants weighted associations with CAD per 10 mg/dl lower LDL-C in CARDIoGRAMplusC4D 
and UK Biobank 
 
variant Conditional 
LDL-C ES 
CARDIoGRAM 
ES 
CARDIoGRAM 
SE 
UK Biobank 
ES 
UK Biobank 
SE 
rs36005199 -0.94 -0.6064 0.1319 -0.2168 0.1151 
rs55674565 -1.25 -0.3312 0.0776 -0.1469 0.0808 
rs2883233 -0.68 -0.6382 0.2471 -0.0888 0.1037 
rs117335915 -1.83 0.1667 0.1902 -0.1208 0.0801 
rs113201466 -0.99 -0.3859 0.2283 -0.1547 0.1346 
rs62075782 -0.98 0.1016 0.1541 -0.1658 0.1324 
rs145940140 -1.97 -0.3706 0.3487 -0.1224 0.1362 
rs143382920 -1.19 -0.6538 0.5462 -0.1421 0.2500 
rs117981684 -0.84 -0.6738 0.4000 0.3822 0.4610 
      
Inverse-variance Meta-analysis  -0.3121 0.0537 -0.1370 0.0388 
      
  ES SE OR(95%CI) 
Combined Cardiogram & UKBB 
(per 10 mg/dl lower LDL-C) 
 -0.1997 0.0311 0.819 (0.770-0.871) p=1.5E-10 
      
 
NB: associations weighted by LDL-C effect size from conditional analyses as presented in Table 2, and scaled per 10 mg/dl 
lower LDL_C using ratio of ES method  
 
 
When combined, the statistical evidence for an association between the ACLY score and the risk of 
CV events was robust (p = 1.5E-10 to 5.0E-11). 
 
Furthermore, the ACLY score was associated with both major coronary events when analysed as a 
score calculated for each individual participant in the UK Biobank:    
 
Table 9:  Individual participant data unweighted and weighted ACLY scores association with MCVE in UK Biobank 
 
ACLY score CAD ES CAD SE P value 
    
Unweighted ACLY score above v below median -0.0482 0.0139 9.33E-04 
(Adjusted per 10 mg/dl lower LDL-C for 2.51 mg/dl 
lower observed difference in LDL-C) 
-0.1920 0.0552 9.33E-04 
    
OR (95% CI) per 10 mg/dl lower LDL-C:   0.825 (0.741 -0.920) 
    
Weighted ACLY score above v below median -0.0469 0.0134 8.38E-04 
(Adjusted per 10 mg/dl lower LDL-C for 2.46 mg/dl 
lower observed difference in LDL-C) 
-0.1905 0.0544 8.38E-04 
    
OR (95% CI) per 10 mg/dl lower LDL-C:   0.827 (0.743 - 0.920) 
    
 
NB: associations weighted by LDL-C effect size observed for difference in LDL-C between participants with ACLY scores 
above and below median 
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The data above are those data that were available at the time and included in our manuscript.  With 
the release of the updated outcomes data, the ACLY score remains robustly associated with the risk 
of both major cardiovascular events (MCVE) and major coronary events (MCE) in UK Biobank. 
 
We note here that the definition and coding of MCE was performed by the UK Biobank 
Cardiometabolic working group (and not by the authors). The definition and coding of MCVE was 
simply MCE or ischemic stroke (a subset of the total stroke variable in UK Biobank). The variables 
ischemic stroke and MCVE were extracted and coded by the Cardiovascular Epidemiology Unit at the 
University of Cambridge and used across all studies using UK Biobank data for all investigators.  
Table 10 shows the associations of the ACLY genetic score with both MCVE and MCE in the most 
updated release of the UK Biobank data, as well as the associations of each variant included in the 
ACLY score with MCVE and MCE:  
 
Table 10:  Individual ACLY score variants associations with MCVE and MCE in UK Biobank  
 
variant Exposur
e allele 
Exposure 
allele 
frequency 
MCVE ES MCVE SE MCVE 
P value 
MCE OR MCE SE MCE 
P value 
rs36005199 G 0.779 -0.0161 0.0098 9.9E-02 -0.0192 0.0105 6.9E-02 
rs55674565 T 0.379 -0.0147 0.0090 1.1E-01 -0.0192 0.0097 4.9E-02 
rs2883233 C 0.130 -0.0066 0.0108 5.4E-01 -0.0079 0.0117 5.0E-01 
rs117335915 T 0.978 -0.0279 0.0234 2.3E-01 -0.0293 0.0252 2.5E-01 
rs113201466 G 0.950 -0.0077 0.0205 7.0E-01 -0.0170 0.0221 4.4E-01 
rs62075782 A 0.223 -0.0198 0.0104 5.7E-02 -0.0141 0.0112 2.1E-01 
rs145940140 T 0.991 -0.0448 0.0523 3.9E-01 -0.0464 0.0563 4.1E-01 
rs143382920 A 0.993 -0.0391 0.0334 2.4E-01 -0.0241 0.0361 5.0E-01 
rs117981684 G 0.979 0.0072 0.0326 8.3E-01 0.0360 0.0355 3.1E-01 
         
Inverse-variance Meta-analysis OR: 0.985 (0.976-0.994) 
 
P = 1.2E-03 OR: 0.984 (0.975-0.994) P = 1.6E-03 
         
OR per 10 mg/dl lower LDL-C weighted 
by marginal effects on LDL in UKBB 
OR: 0.710 (0.558-0.904) P = 8.0E-03   
         
OR per 10 mg/dl lower LDL-C meta-
analysis weighted by conditional effects 
on LDL in UKBB 
OR: 0.686 (0.519-0.907) P = 5.4E-03   
         
 
NB: rs34349578 did not pass QC in UK Biobank, so rs36005199 was used as the nearest proxy (r2=0.91). Data from 351,267 
participants of self-identified White ancestry not on current lipid lowering therapy, adjusted for age gender and the first 
five principal components 
 
As compared to the analyses using the previous release of the data (and the analyses in our 
manuscript that were restricted to the 367,000 participants who self-identified as being of White 
British ancestry who were unrelated to all other participants as defined by a kinship coefficient > 
0.044), the ACLY score remains associated with both MCVE and MCE in UK Biobank.   
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Table 11 below presents the associations of the ACLY score calculated for each participant in UK 
Biobank: 
 
Table 11:  Associations of ACLY genetic scores with MCVE and MCE in UK Biobank  
 
ACLY Score MCVE OR (95% CI) MCVE 
p value 
MCE OR (95% CI) MCE 
p value 
     
Continuous variable scores 
     
Unweighted score 0.990 (0.982-0.997) 6.7E-03 0.989 (0.981-0.997) 8.5E-03 
Score weighted by conditional LDL ES (NEJM) 0.990 (0.982-0.997) 4.1E-03 0.989 (0.981-0.997) 4.8E-03 
Score weighted by conditional LDL ES UKBB 0.965 (0.940-0.991) 1.0E-02 0.966 (0.939-0.993) 1.9E-02 
     
Dichotomous scores as an instrument of randomization dividing participants with scores above and below median  
     
Unweighted score 0.958 (0.930-0.987) 4.7E-03 0.957 (0.932-0.983) 3.6E-03 
Score weighted by conditional LDL ES (NEJM) 0.969 (0.946-0.993) 1.1E-02 0.964 (0.939-0.989) 5.4E-03 
Score weighted by conditional LDL ES UKBB 0.972 (0.950-0.996) 2.3E-02 0.972 (0.948-0.997) 3.2E-02 
     
 
NB: rs34349578 did not pass QC in UK Biobank, so rs36005199 was used as the nearest proxy (r2=0.91). Data from 351,267 
participants of self-identified White ancestry not on current lipid lowering therapy, adjusted for age gender and the first 
five principal components 
 
 
Regardless of whether analysed as a continuous variable or a dichotomous instrument of 
randomization, and regardless of whether the scores were unweighted, weighted by the conditional 
weights used in our manuscript, or weighted by the conditional effect of each variant on LDL-C 
calculated from the UK Biobank lipid data, the ACLY score was associated with a lower risk of both 
MCVE and MCE (with effect sizes very similar to the effect sizes reported in our original manuscript).   
 
We note here a methodologic consideration. Ultimately, Mendelian randomization is merely an 
instrument of randomization, without any further assumption.  Therefore, the least biased analysis is 
to simply use the unweighted genetic score as an instrument of randomization to divide the sample 
into groups and measure the observed differences between LDL-C and cardiovascular events 
between the groups being compared. When these analyses are performed in UK Biobank, as shown 
in Tables 6, 9 and 11, the ACLY score is strongly associated with both lower LDL-C and lower CVD.  
 
By contrast, adjusting the CVD effect size of each variant included in the score by the corresponding 
effect size of that variant on LDL-C (which is the conventional Wald ratio method) is potentially 
treacherous when analysing a score that by design is constructed to improve the association of 
variants weakly associated with the exposure.  This is because in the Wald ratio method (and other 
similar methods of adjustment), the outcome effect size (and corresponding standard error) for each 
variant is divided by the exposure effect size for that variant (the so-called usual ratio of effect sizes 
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method).  From this explanation it becomes clear that the uncertainty captured the variance of the 
association between the variant and the outcome is incorporated into the “adjusted” effect estimate 
because both the effect size and the corresponding standard error are divided by the same number, 
thus preserving the measure of uncertainty.  By contrast, the association between the variant and 
the exposure is assumed to be so robust that it does not have any practical variability.  While this is 
true for variants strongly associated with exposures at genome-wide level of statistical significance 
where the SE and corresponding confidence intervals are exceedingly small, it is distinctly not the 
case when using variants weakly associated with the exposure, such as the weak associations 
between genetic variants in the ACLY gene region and LDL-C, where the confidence intervals for the 
associations with LDL-C are wide for most variants.   
 
Therefore, “adjusting” the CVD effect size (and corresponding SE) for the variants included in the 
ACLY score by their imprecise estimate of effect size for LDL-C can potentially lead to unstable 
“adjusted” point estimates of effect that disagree when performed in different populations using 
different weights (where the weights can be quite different due to the relatively wide confidence 
interval of the association with the exposure).   
 
Therefore, the most “fair” (unbiased) way to compare the effect sizes of the associations of the ACLY 
score in different populations, or combine the effect sizes across populations, is to use the 
unweighted genetic score as an instrument of randomization only (without further assumptions) and 
use the observed  differences in LDL-C and CV events among the groups being compared to calculate 
the association of the ACLY score with LDL-C and risk of cardiovascular disease.  These analyses are 
presented in Tables 6, 9 and 11 – and show that the “unweighted” ACLY score is robustly associated 
with LDL-C and CV events when used as an unbiased instrument of randomization (which has the 
least statistical power but also has the least potential bias). 
 
Therefore, based on the analyses presented above, we conclude that the ACLY score that we 
constructed to be an instrument that mimics the effect of ACL inhibition is strongly associated with 
lower plasma LDL-C, concordantly lower plasma apoB (strongly suggesting that the score is 
instrumenting a mechanism that lowers LDL-C through the LDL receptor pathway), and a 
corresponding lower risk of cardiovascular events.   Therefore, the overall three-stage approach we 
used to construct the score consisting of several variants weakly associated with the biomarker 
reflecting the pharmacologic action of ACL inhibition does appear to instrument the effect of ACL 
inhibition.  
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Further evidence that the ACLY score is instrumenting the effect of ACL inhibition in UK Biobank 
 
As noted above, the ACLY score was designed to create an instrument that mimics the effect of ACL 
inhibition.  Unfortunately, there is no current biological evidence that the variants included in our 
ACLY score are associated with changes in ACLY gene expression, or ACL structure or function. We 
note, however, that among the 250 variants that have been reported to be associated with ACLY 
expression in GTEx, only 3 are independently inherited and only one is weakly associated with 
plasma LDL-C (rs2304497 – a protein truncating variant within the ACLY gene that was reported to 
be weakly associated with lower LDL-C among 280K participants of exome analysis of the Global 
Lipids Genetics Consortium with a p value of 0.01).22  
 
Release of the biomarker data from UK Biobank after the publication of our manuscript provides an 
opportunity to further evaluate whether our ACLY genetic score is instrumenting the effect of ACL 
inhibition.  
 
Because the objective of our study was to construct an instrument that mimics the effect of ACL 
inhibition, the best biological evidence to make inferences about whether our genetic score may be 
instrumenting ACL inhibition are biochemical and clinical changes observed in randomized trials 
evaluating the inhibition of ACL by bempedoic acid.   
 
In randomized trials, inhibiting ACL with bempedoic acid lowers LDL-C, concordantly lowers apoB (by 
inhibiting cholesterol biosynthesis leading to the up-regulation of LDL receptors), and is associated 
with lower body weight, lower HgbA1C, and lower diabetes risk.12-15    
 
We noted above that the ACLY score is associated with both lower LDL-C and concordantly lower 
apoB in UK Biobank thus suggesting that the score is instrumenting a mechanism that lowers LDL-C 
through the LDL receptor pathway.   
 
In addition, as shown in Table 12 below, like ACL inhibition with bempedoic acid, our ACLY score is 
also associated with lower weight, lower HgbA1C, and lower risk of diabetes in the UK Biobank.  
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Table 12:  Association of unweighted and weighted ACLY scores with biomarkers and diabetes in UK Biobank 
 
Biomarker or 
phenotype 
Unweighted 
score ES 
continuous 
Unweighted 
score SE 
continuous 
Unweighted 
score p 
continuous 
Unweighted 
score ES 
dichotomous 
Unweighted 
score SE 
dichotomou
s 
Unweighted 
score p 
dichotomou
s 
       
Weight (kg) -0.061 0.013 4.6E-06 -0.143 0.043 9.0E-04 
HgbA1C (%) -0.035 0.006 1.5E-08 -0.097 0.020 1.1E-06 
Diabetes 0.990 0.003 1.8E-04 0.974 0.008 1.9E-03 
 (0.984-0.996)   (0.959-0.989)   
 
NB: associations unweighted scores treated as a continuous variable and as dichotomous instrument of randomization 
comparing participants with scores above v. below median.  A total of 444,560 participants who self-identified white 
ancestry were included in the analysis, adjusted for age gender and the first five principal components.  NB: rs34349578 
did not pass QC in UK Biobank, so rs36005199 was used as the nearest proxy (r2=0.91). 
 
These data independently confirm the results that we included in our original manuscript, showing 
that the ACLY score was associated with lower weight (and lower BMI), and lower risk of diabetes 
using data from the GIANT and DIAGRAM consortia, respectively.27,28   
 
Therefore, our ACLY genetic score appears to have the same clinical profile as inhibiting ACL with 
bempedoic acid.   
 
Furthermore, as shown in Table 13, this clinical profile is a very unusual and is distinctly different 
than the clinical profile of variants in the HMG-CoA reductase gene that encodes the target of 
statins, and very different than the clinical profile of treatment with a statin – both of which have 
been shown to lower LDL-C and lower apoB concordantly, but to also INCREASE weight, INCREASE 
HgbA1C, and INCEASE the risk of diabetes. 
 
 
Table 13:  Comparison of ACLY score with Bempedoic acid (ACL inhibitor), HMGCR score, statins, and generic LDL-C score 
 
Genetic score of Therapy LDL-C apoB CAD weight HgbA1C Diabetes 
       
ACLY score  decrease decrease decrease decrease decrease decrease 
ACL inhibitor (Bempedoic acid) decrease decrease ? decrease decrease decrease 
       
HMGCR score decrease decrease decrease increase increase increase 
statins decrease decrease decrease increase increase increase 
102 variant LDL genetic score decrease decrease decrease increase increase increase 
       
 
This difference is biologically plausible because ACL is located upstream to HMG-CoA reductase 
proximal to the bifurcation of the lipid pathway into the cholesterol biosynthesis and intrinsic fatty 
metabolism pathways.   
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In addition, as shown in Table 13 above, the clinical profile of our ACLY score and ACL inhibition with 
bempedoic acid is also distinctly different than the clinical profile of a generic LDL-C score composed 
of 100 variants associated with LDL-C at genome-wide level of significance.  Like HMG-CoA reductase 
variants and statins, this generic LDL-C instrumental variable genetic score is also associated with 
lower LDL-C, concordantly lower apoB (because reducing LDL particles through the LDL receptor is 
the predominant biological mechanism for changes in plasma LDL-C), but an INCREASE in weight, 
INCREASE in HgbA1C, and an INCEASE the risk of diabetes.   
 
 The difference in the clinical profile between our ACLY score and the generic LDL-C instrumental 
variable genetic score strongly suggests that our ACLY score is not instrumenting a generic LDL-C 
lowering mechanism, or some other gene in the region that may lower LDL-C through the LDL 
receptor pathway, but instead is instrumenting a very specific mechanism of lowering LDL-C.  We 
note that the only gene in this region that is known to be involved in lipid metabolism, and the only 
gene in the region known to code for a protein that when inhibited leads to lower plasma LDL-C with 
a clinical profile that is distinctly different than the clinical profile of other mechanism of lowering 
LDL-C is ACLY.   
 
ACLY score also mimics effect of an ACLY protein truncating mutation 
 
The release of the biomarker data from UK Biobank also allows a closer evaluation of the only 
protein truncating mutation in ACLY that is associated with lower LDL-C.  As noted above, this variant 
has been reported to be weakly associated with lower LDL-C (0.3 mg/dl, p=0.01) in the exome 
analysis of 280K participants in the Global Lipids Genetics Consortium, and associated with a 
concordantly (but non-significantly) lower risk of CAD (p=0.65) in the Myocardial Infarction Genetics 
and CARDIoGRAM Exome meta-analysis of Exome-chip studies including 42,335 patients and 78,240 
controls of European descent.29,30   
 
Table 14 shows that this protein truncating ACLY variant is associated with lower LDL-C (p=0.012), 
concordantly lower apoB (p=0.001), and a corresponding lower risk of major cardiovascular events 
(p=0.026) among participants enrolled in the UK Biobank.   
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 Table 14:  Associations of ACLY protein truncating variant rs2304497 with biomarkers and outcomes in UKBB 
 
Biomarker Effect size (mg/dl) SE P value 
    
LDL-C -0.337 0.1342     0.012 
apoB -0.313 0.0954 0.001 
    
Outcomes OR (95% CI) P value 
    
MCVE 0.964 (0.934 - 0.995)     0.026   
Diabetes 0.981 (0.962 - 0.999) 0.048 
    
 
NB: associations of rs2304497 as dichotomous variable (carrier v. non-carriers).  Analysis includes 364,128 unrelated UK 
Biobank participants self-identified as of white European ancestry, including 23,914 participants who experienced a first 
major cardiovascular event (defined as the first occurrence of fatal or non-fatal MI, ischemic stroke, coronary 
revascularization of CHD death).    
 
Remarkably, however, Table 14 also shows that this ACLY protein truncating variant is also 
associated with a lower risk of diabetes – just like our ACLY score and ACL inhibition with bempedoic 
acid – but very different from HMGCR, NPC1L1, PCSK9, and LDLR variants, the 100-variant generic 
LDL-C instrumental variable genetic score, and treatment with a statin. 
 
Therefore, our ACLY genetic score appears to have the same clinical profile as inhibiting ACL with 
bempedoic acid AND the same clinical profile as the protein truncating variant in ACLY.  Together, 
these finding provide independent “genetic target validation” for ACLY as a therapeutic target.   
 
Of course, it is possible that all these findings, replicated in multiple independent data sets, 
demonstrating a remarkably similar clinical profile of our ACLY score with the distinct clinical profile 
of ACL inhibition by bempedoic acid and decreased ACLY expression due to a protein truncating 
mutation in ACLY, could have occurred repeatedly by chance alone. However, that would be highly 
unlikely.   
 
Therefore, we believe that it is reasonable to conclude that our ACLY genetic score does appear to 
instrument the effects of ACL inhibition, precisely what it was designed to do.  
   
Further evidence ACLY genetic target validation in UK Biobank 
 
The release of the biomarker data in the very large UK biobank also provides an opportunity to 
identify other rare variants within the ACLY gene that may be more strongly associated with LDL-C 
than common variants within and immediately around the ACLY gene.  Despite an exhaustive, and 
computationally intensive, search over several weeks we were not able to identify any common or 
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rare variants, either alone or in combination, that were strongly associated with LDL-C or that 
performed better than our ACLY score.    
 
However, because the overwhelming majority of the 80 million imputed variants in the UK Biobank 
are rare variants (defined as having a MAF < 0.001), we were able to identify 64 independently 
inherited rare variants physically located within the ACLY gene itself (and not correlated with any 
other rare variant in the gene in individual participant analysis).  The position of these variants 
within the ACLY gene are shown in the Figure: 
 
Figure 1: 63 rarer variants (MAF < 0.005) within ACLY gene 
 
 
 
 
 
 
 
 
 
 
 
 
 
And their variant ID is provided in Table 15: 
 
Table 15: Score composed of 63 rarer variants (MAF < 0.005) within ACLY gene 
 
variant position maf 
rs569956064 chr17:40023204 0.0008991 
rs563786739 chr17:40023228 0.00067755 
rs548321878 chr17:40029424 0.0004447 
rs530924991 chr17:40030342 0.0008898 
rs547756441 chr17:40030405 0.0000606 
rs574160463 chr17:40032696 0.00025955 
rs574160463 chr17:40032696 0.00025955 
rs564030902 chr17:40032821 0.0003101 
rs559347356 chr17:40035238 0.00038395 
rs567423785 chr17:40035308 0.00002665 
rs148678599 chr17:40035629 0.00272075 
rs570073390 chr17:40037494 0.0021912 
rs558276594 chr17:40038267 0.000186 
rs530613844 chr17:40038429 0.00057075 
rs533674970 chr17:40039824 0.0004665 
rs537210980 chr17:40040601 0.000761 
rs545020635 chr17:40041378 0.00408445 
rs148168367 chr17:40042392 0.0003839 
rs543772994 chr17:40043623 0.0005341 
rs375260598 chr17:40043818 0.00031125 
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rs546239739 chr17:40044188 0.0000698 
rs570075468 chr17:40044334 0.0001076 
rs148187302 chr17:40051492 0.00005265 
rs552588596 chr17:40052037 0.00017415 
rs576082417 chr17:40052389 0.00093145 
rs539879906 chr17:40053308 0.0005174 
rs539640648 chr17:40054734 0.0002288 
rs147986968 chr17:40055060 0.0001331 
rs534309713 chr17:40055847 0.00009205 
rs555851654 chr17:40055972 0.0001134 
rs537902727 chr17:40056573 0.00058645 
rs372995526 chr17:40056852 0.000046 
rs146590388 chr17:40057400 0.0000166 
rs535070215 chr17:40057818 0.0000561 
rs547189634 chr17:40059061 0.0001693 
rs574198943 chr17:40059639 0.00005395 
rs552795756 chr17:40060324 0.00170425 
17:40060658_GGAAA_G chr17:40060658 0.0007278 
rs201593092 chr17:40061926 0.00106985 
rs373894224 chr17:40062879 0.00132455 
rs782020021 chr17:40064533 0.0006678 
rs567286666 chr17:40064835 0.001309 
rs563759499 chr17:40065570 0.00029765 
rs564026336 chr17:40066132 0.00117195 
rs190339613 chr17:40066728 0.000602 
rs183698275 chr17:40066946 0.00003925 
rs570386216 chr17:40066986 0.00002215 
rs573534177 chr17:40067366 0.00144025 
rs186180080 chr17:40067409 0.00029155 
rs533177674 chr17:40067573 0.00040585 
rs574130210 chr17:40068116 0.000096 
rs574130210 chr17:40068116 0.000096 
rs147768074 chr17:40068646 0.00044255 
rs185147441 chr17:40071485 0.00103795 
rs570137216 chr17:40071496 0.00003725 
rs543021562 chr17:40071913 0.00024415 
rs558254673 chr17:40073128 0.00373955 
rs387907380 chr17:40075176 0.0003477 
rs528987483 chr17:40075268 0.0002518 
rs116797867 chr17:40076575 0.0000564 
rs562369323 chr17:40078478 0.0011736 
rs538819381 chr17:40079774 0.00009025 
rs747583969 chr17:40082520 0.0006775 
 
 
As shown in Table 16, UK Biobank participants who carried one or more of these rare variants had an 
average of 1.3 mg/dL lower LDL-C (p<3.2E-08), and a corresponding 2-3% lower risk of major 
coronary events (p= 0.015) as compared to non-carriers.  
 
Table 16:  ACLY score consisting of 63 rarer variants within ACLY gene association with LDL-C and CAD in UKBB 
 
UK Biobank population ancestry LDL-C es LDL-C se LDL-C p CAD es CAD se CAD p 
       
367,643 unrelated, British, white ancestry   -1.2729 0.2302 3.2E-08 -0.0759 0.0288 0.0147 
       
459,322 self-identified white ancestry -1.2846 0.2100 9.4E-10 -0.0551 0.0263 0.0477 
       
 
 
Although not compelling, and only marginally useful for attempting to “provide a biological context 
for interpreting the results of prior ACL inhibitor randomized trials, inform the design of future trials, 
and estimate the clinical effect of lowering plasma LDL-C by inhibiting ACL” (which was the purpose 
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of our study), together with the data for the common ACLY protein truncating variant, these data do 
provide further “genetic target validation” for ACL inhibition as a therapeutic target. 
 
Conclusion 
The genes that encode the targets of most therapies do not have rare variants with large-effect or 
common variants with moderate effects on the biomarker reflecting the pharmacologic action of the 
corresponding therapy.  Therefore, to provide “genetic target validation”, to provide naturally 
randomized genetic evidence to help guide the evaluation and development of these therapies, or to 
provide a biological context for interpreting the results of randomized trials evaluating these 
therapies is challenging.  Novel methods are being developed to combine multiple variants in the 
gene encoding the target of a therapy that are weakly associated with the biomarker reflecting the 
pharmacologic action of the therapy into a genetic score that can be used to “instrument” the 
therapy.  This is an active area of research that is rapidly evolving. We provided one example of an 
approach to solve this important problem.  Developing methods to create robust genetic 
instruments for a much greater number of potential therapeutic targets is critical for improving the 
role of Mendelian randomization in the drug discovery and development process.31   
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